Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. haematol [Internet]. 2023Feb.1 [cited 2026Apr.11];108(2):457-71. Available from: https://haematologica.org/article/view/haematol.2022.281456